85
Views
4
CrossRef citations to date
0
Altmetric
Original Research

De-Intensification Of Blood Glucose Lowering Medication In People Identified As Being Over-Treated: A Mixed Methods Study

ORCID Icon, , ORCID Icon, ORCID Icon, , ORCID Icon & ORCID Icon show all
Pages 1775-1783 | Published online: 18 Oct 2019

References

  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.9742976
  • Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. doi:10.1056/NEJMoa080647018784090
  • Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med. 2014;174(5):678–686. doi:10.1001/jamainternmed.2014.13624615164
  • Signorovitch JE, Macaulay D, Diener M, et al. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes Obes Metab. 2013;15(4):335–341. doi:10.1111/dom.1203123121373
  • Zaccardi F, Davies MJ, Dhalwani NN, et al. Trends in hospital admissions for hypoglycaemia in England: a retrospective, observational study. Lancet Diabetes Endocrinol. 2016;4(8):677–685. doi:10.1016/S2213-8587(16)30091-227293218
  • Majumdar SR, Hemmelgarn BR, Lin M, McBrien K, Manns BJ, Tonelli M. Hypoglycemia associated with hospitalization and adverse events in older people. Diabetes Care. 2013;36(11):3585LP–3590. doi:10.2337/dc13-052324089536
  • Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–1418. doi:10.1056/NEJMoa100379520925543
  • Fitzpatrick C, Chatterjee S, Seidu S, et al. Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(9):2169–2178. doi:10.1111/dom.1334829740922
  • Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. Bmj. 2010;340:b4909. doi:10.1136/bmj.b490920061358
  • American Diabetes Association. 11. Older adults. Diabetes Care. 2017;40(Suppl1):S99–S104. doi:10.2337/dc17-S01427979898
  • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–1596. doi:10.1007/s00125-012-2534-022526604
  • Rutten GEHM, de Grauw WJC, Nijpels G, et al. NHG-standaard diabetes mellitus type 2 (derde herziening). Huisarts Wet. 2013;56(10):512–525.
  • Arnold SV, Lipska KJ, Wang J, Seman L, Mehta SN, Kosiborod M. Use of intensive glycemic management in older adults with diabetes mellitus. J Am Geriatr Soc. 2018. doi:10.1111/jgs.15335
  • Maciejewski ML, Mi X, Sussman J, et al. Overtreatment and deintensification of diabetic therapy among medicare beneficiaries. J Gen Intern Med. 2018;33(1):34–41. doi:10.1007/s11606-017-4167-y28905179
  • Hambling CE, Seidu S, Davies MJ, Khunti K. Older people with type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies. Diabet Med. 2017. doi:10.1111/dme.13380
  • Dejager S, Penfornis A, Fiquet B, Blickle JF. Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study. Diabetes Metab Syndr Obes Targets Ther. 2015;8:303. doi:10.2147/DMSO.S83897
  • Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015;175(3):356–362. doi:10.1001/jamainternmed.2014.734525581565
  • Andreassen LM, Sandberg S, Kristensen GBB, UØ S, Kjome RLS. Nursing home patients with diabetes: prevalence, drug treatment and glycemic control. Diabetes Res Clin Pract. 2014;105(1):102–109. doi:10.1016/j.diabres.2014.04.01224853809
  • Müller N, Khunti K, Kuss O, et al. Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study. Acta Diabetol. 2017;54(2):209–214. doi:10.1007/s00592-016-0939-927837286
  • Khunti K, Davies MJ. Clinical inertia-time to reappraise the terminology?. Prim Care Diabetes. 2017;11(2):105–106. doi:10.1016/j.pcd.2017.01.00728222959
  • Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018:dci180033. doi:10.2337/dci18-0033
  • Rutten GEHM, Alzaid A. Person-centred type 2 diabetes care: time for a paradigm shift. Lancet Diabetes Endocrinol. 2018;6(4):264–266. doi:10.1016/S2213-8587(17)30193-628606729
  • Hart HE, Rutten GE, Bontje KN, Vos RC. Overtreatment of older patients with type 2 diabetes mellitus in primary care. Diabetes Obes Metab. 2018;20(4):1066–1069. doi:10.1111/dom.1317429193555
  • Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–567. doi:10.1016/S0022-3999(99)00057-410661603
  • Sussman JB, Kerr EA, Saini SD, et al. Rates of deintensification of blood pressure and glycemic medication treatment based on levels of control and life expectancy in older patients with diabetes mellitus. JAMA Intern Med. 2015;175(12):1942–1949. doi:10.1001/jamainternmed.2015.511026502220
  • Vimalananda VG, DeSotto K, Chen T, et al. A quality improvement program to reduce potential overtreatment of diabetes among veterans at high risk of hypoglycemia. Diabetes Spectr. 2017;30(3):211–216. doi:10.2337/ds16-000628848316
  • Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA. 2016;315(10):1034–1045. doi:10.1001/jama.2016.029926954412
  • Formiga F, Vidal X, Agusti A, et al. Inappropriate prescribing in elderly people with diabetes admitted to hospital. Diabet Med. 2016;33(5):655–662. doi:10.1111/dme.1289426333026
  • Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitusitle. Diabetes Metab. 2017;43(6):501–511. doi:10.1016/j.diabet.2017.06.00328754263
  • Crowley MJ, Smith VA, Olsen MK, Danus S, Oddone EZ, Bosworth HBPB. Treatment intensification in a hypertension telemangement trial. Clinical inertia or good clinical judgment. Hypertension. 2011;58(4):552–558. doi:10.1161/HYPERTENSIONAHA.111.17436721844490
  • Persell SD, Dolan NC, Friesema EM, Thompson JA, Kaiser DBD. Frequency of inappropriate medical exceptions to quality measures. Ann Intern Med. 2010;152(4):225–231. doi:10.7326/0003-4819-152-4-201002160-0000720157137
  • Safford M, Shewchuk R, Williams JH, Estrada CA, Ovalle FAJ. Reasons for not intensifying medications: differentiating “clinical inertia” from appropriate care. J Gen Intern Med. 2007;22(12):1648–1655. doi:10.1007/s11606-007-0433-817957346
  • Caverly TJ, Fagerlin A, Zikmund-Fisher BJ, et al. Appropriate prescribing for patients with diabetes at high risk for hypoglycemia. JAMA Intern Med. 2015;175(12):1994. doi:10.1001/jamainternmed.2015.595026502113
  • von Arx L-B, Kjær T. The patient perspective of diabetes care: a systematic review of stated preference research. Patient Patient Centered Outcomes Res. 2014;7(3):283–300. doi:10.1007/s40271-014-0057-0
  • Svedbo Engström M, Leksell J, Johansson U-B, Gudbjörnsdottir S. What is important for you? A qualitative interview study of living with diabetes and experiences of diabetes care to establish a basis for a tailored patient-reported outcome measure for the Swedish National Diabetes Register. BMJ Open. 2016;6(3):e010249. doi:10.1136/bmjopen-2015-010249